COVID-19-associated pulmonary aspergillosis in a Japanese man : A case report
Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
CAPA (COVID-19 associated pulmonary aspergillosis) is an important complication of COVID-19. It has been reported that the incidence of CAPA is as high as 19%-33% worldwide. However, its onset has not been reported in Japan. A 72-year-old Japanese man was diagnosed with COVID-19 and was transferred to our hospital due to deterioration of respiratory condition. Treatment with remdesivir, dexamethasone (DEXA), and antibiotics was performed under mechanical ventilation. Although the condition improved temporarily, a new shadow appeared in the lung, and Aspergillus fumigatus was cultured from sputum. The patient was clinically diagnosed with CAPA and treated with voriconazole. However, his progress deteriorated and he died. High-risk COVID-19 patients should be tested for Aspergillus to ensure early diagnosis of CAPA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 27(2021), 6 vom: 01. Juni, Seite 911-914 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Imoto, Waki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 13.05.2021 Date Revised 27.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiac.2021.02.026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32231478X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32231478X | ||
| 003 | DE-627 | ||
| 005 | 20231225181758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiac.2021.02.026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM32231478X | ||
| 035 | |a (NLM)33674201 | ||
| 035 | |a (PII)S1341-321X(21)00066-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Imoto, Waki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19-associated pulmonary aspergillosis in a Japanese man |b A case report |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.05.2021 | ||
| 500 | |a Date Revised 27.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a CAPA (COVID-19 associated pulmonary aspergillosis) is an important complication of COVID-19. It has been reported that the incidence of CAPA is as high as 19%-33% worldwide. However, its onset has not been reported in Japan. A 72-year-old Japanese man was diagnosed with COVID-19 and was transferred to our hospital due to deterioration of respiratory condition. Treatment with remdesivir, dexamethasone (DEXA), and antibiotics was performed under mechanical ventilation. Although the condition improved temporarily, a new shadow appeared in the lung, and Aspergillus fumigatus was cultured from sputum. The patient was clinically diagnosed with CAPA and treated with voriconazole. However, his progress deteriorated and he died. High-risk COVID-19 patients should be tested for Aspergillus to ensure early diagnosis of CAPA | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19-Associated pulmonary aspergillosis | |
| 650 | 4 | |a Coronavirus disease | |
| 650 | 4 | |a Invasive pulmonary aspergillosis | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Himura, Hoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuo, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Kawata, Sae |e verfasserin |4 aut | |
| 700 | 1 | |a Kiritoshi, Ayako |e verfasserin |4 aut | |
| 700 | 1 | |a Deguchi, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Miyashita, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kaga, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Noda, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Katsumi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Tetsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Hiromasa |e verfasserin |4 aut | |
| 700 | 1 | |a Mizobata, Yasumitsu |e verfasserin |4 aut | |
| 700 | 1 | |a Kakeya, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |d 1996 |g 27(2021), 6 vom: 01. Juni, Seite 911-914 |w (DE-627)NLM095488073 |x 1437-7780 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:6 |g day:01 |g month:06 |g pages:911-914 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiac.2021.02.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 6 |b 01 |c 06 |h 911-914 | ||